Clinical Trials

    A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared With Investigator Choice in HLA-A*0201 Positive Patients With Previously Untreated Advanced Uveal Melanoma

    Investigator: Anaum Maqsood

    Study Coordinator: Safiya Joseph

    Status: Open Not Enrolling

    ClinicalTrials.gov Number: NCT03070392

    Phone: 203.308.8567

    Protocol Number: Pro00021862

    Description


    To evaluate the overall survival of HLA-A*0201 positive adult patients with previously untreated advanced UM receiving IMCgp100 compared to Investigator's Choice of dacarbazine, ipilimumab, or pembrolizumab.